Inotiv Launches Website for Newly Unified Contract Research Services
February 12 2020 - 9:18AM
Bioanalytical Systems, Inc. (NASDAQ: BASI), operating as Inotiv
(the “Company” or “Inotiv”), is pleased to announce the launch of
its new website, inotivco.com. The website reinforces the Company’s
new brand, “Inotiv,” which symbolizes the union of legacy contract
research services with those acquired in the Seventh Wave
Laboratories, Smithers Toxicology Services, and Pre-Clinical
Research Services acquistions. Inotiv provides top-tier in vivo
toxicology, pharmacology, drug metabolism, bioanalysis,
pharmacokinetic, and surgical and medical device discovery and
development solutions.
“The website expresses our bold new brand and Inotiv’s
philosophy, expect more,” said Company President and Chief
Executive Officer Robert Leasure, Jr. “It reflects our fundamental
goal: Deliver excellent client experiences.”
Over the past year, the Company has worked hard and invested in
program management and processes to coordinate teams and services
at all of the Company’s sites, moving from a collective of broad
responsibilities to more focused teams that are integrated and
aligned with key client and internal needs.
We believe the brand presents a comprehensive portfolio of
complementary resources and capabilities that enable the timely
delivery of focused, actionable insights that help drug developers
succeed in today’s competitive market.
Visit the new Inotiv website at inotivco.com.
About the Company
Bioanalytical Systems, Inc., operating as
Inotiv, is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development
companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients’ discovery
and development objectives for improved decision-making and
accelerated goal attainment. The Company’s products focus on
increasing efficiency, improving data, and reducing the cost of
taking new drugs to market. Visit inotivco.com for more
information about the Company.
This release may contain forward-looking
statements that are subject to risks and uncertainties including,
but not limited to, risks and uncertainties related to changes in
the market and demand for our products and services, the
development, marketing and sales of products and services, changes
in technology, industry and regulatory standards, the timing of
acquisitions and the successful closing, integration and business
and financial impact thereof, and various market and operating
risks, including those detailed in the Company's filings with the
U.S. Securities and Exchange Commission.
Company Contact:Jill C.
BlumhoffChief Financial OfficerPhone:
765.497.8381jblumhoff@inotivco.com
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2024 to May 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From May 2023 to May 2024